Label ruling upends generic medicine makers
The effects of the ‘skinny label’ decision are still being felt across pharma. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch revisits GSK v Teva.
Stay updated with breaking news from Fed Cir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The effects of the ‘skinny label’ decision are still being felt across pharma. MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch revisits GSK v Teva.
The US Court of Appeals for the Federal Circuit revived a Petitioner’s validity challenge seeking ex parte review at the US Patent & Trademark Office…
The US Court of Appeals for the Federal Circuit revived a petitioner’s validity challenge seeking ex parte review at the US Patent & Trademark Office (PTO), reversing a district court...
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
A duo of cases from the Federal Circuit has added complexities to the drafting of patent applications for antibody inventions, explain Hailey Bureau of BSKB and Olayinka Oladele of the Thurgood Marshall School of Law.